Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
1(9%)
Results Posted
33%(3 trials)

Phase Distribution

Ph phase_2
1
9%
Ph phase_4
1
9%
Ph phase_1
4
36%
Ph phase_3
3
27%

Phase Distribution

4

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
3(33.3%)
Phase 4Post-market surveillance
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(9)
Other(1)

Detailed Status

Completed9
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (44.4%)
Phase 21 (11.1%)
Phase 33 (33.3%)
Phase 41 (11.1%)

Trials by Status

unknown19%
active_not_recruiting19%
completed982%

Recent Activity

1 active trials
Showing 5 of 11
completedphase_1

A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants

NCT07142642
active_not_recruitingphase_3

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

NCT06248619
completedphase_4

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

NCT05002998
completed

Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients

NCT07085117
completedphase_1

A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)

NCT02103283
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07142642Phase 1

A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants

Completed
NCT06248619Phase 3

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

Active Not Recruiting
NCT05002998Phase 4

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Completed
NCT07085117

Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients

Completed
NCT02103283Phase 1

A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)

Completed
NCT01868997Phase 2

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Completed
NCT06674941Phase 1

A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants

Completed
NCT03298867Phase 3

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

Completed
NCT03461211Phase 3

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study

Completed
NCT06389578Phase 1

A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease

Completed
NCT04040894

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease

Unknown

All 11 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
11